NO20083369L - Anvendelse av substituert 2-imidazol av imidazolinderivater - Google Patents

Anvendelse av substituert 2-imidazol av imidazolinderivater

Info

Publication number
NO20083369L
NO20083369L NO20083369A NO20083369A NO20083369L NO 20083369 L NO20083369 L NO 20083369L NO 20083369 A NO20083369 A NO 20083369A NO 20083369 A NO20083369 A NO 20083369A NO 20083369 L NO20083369 L NO 20083369L
Authority
NO
Norway
Prior art keywords
disorders
benzofuran
lower alkyl
halogen
phenyl
Prior art date
Application number
NO20083369A
Other languages
English (en)
Inventor
Guido Galley
Katrin Groebke Zbinden
Sabine Kolczewski
Roger Norcross
Henri Stalder
Marius Hoener
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38226290&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20083369(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20083369L publication Critical patent/NO20083369L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår anvendelse av forbindelser med formel I I hvor R er hydrogen, tritium, hydroksy, amino, lavere alkyl, sykloalkyl, lavere alkoksy, halogen, cyano, lavere alkyl substituert med halogen, lavere alkoksy substituert med halogen, fenyl, O-fenyl, -S-fenyl, eventuelt substituert med halogen eller er benzyl, benzyloksy, NHC(O)-lavere alkyl eller pyridin-2,3 eller 4-yl; R1 er hydrogen, hydroksy eller lavere alkyl; R2 er hydrogen eller lavere alkyl; aryl er en aromatisk gruppe, valgt fra fenyl, naftalen-1-yl eller naftalen-2-yl; hetaryl er en aromatisk gruppe, inneholdende minst ét O, N eller S ringatom, valgt fra gruppen bestående av pyridin-3-yl, pyrazolyl, benzofuran-3-yl, benzofuran-4-yl, benzofuran-5-yl, benzofuran-6-yl, benzofuran-7-yl, tiofen-2-yl, tiofen-3-yl, benzo[b]tiofen-3-yl eller indol-3-yl; n er 1, 2, 3, 4 eller 5; når n er 2, 3, 4 eller 5, kan R være lik eller ikke; den stiplede linjen kan være en binding eller ikke; og til deres farmasøytiske aktive salter for fremstilling av medikamenter for behandling av depresjon, angst lidelser, bipolar lidelse, oppmerksomhetssvikt hyperaktivitet lidelse, stressrelaterte lidelser, psykotiske lidelser så som schizofreni, nevrologiske sykdommer så som Parkinson's sykdom, neurodegenerative lidelser så som Alzheimer's sykdom, epilepsi, migrene, hypertensjon, stoffmisbruk og metabolsk lidelser så som spiseforstyrrelser, diabetes, diabetiske komplikasjoner, fedme, dyslipidemi, lidelser i energi konsum og assimilasjon, lidelser og feilfunksjon av kroppstemperatur homeostase, søvnlidelser og cirkadisk rytme og kardiovaskulære lidelser.
NO20083369A 2006-01-27 2008-08-01 Anvendelse av substituert 2-imidazol av imidazolinderivater NO20083369L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06100955 2006-01-27
PCT/EP2007/050443 WO2007085557A2 (en) 2006-01-27 2007-01-17 Use of substituted 2-imidazole of imidazoline derivatives

Publications (1)

Publication Number Publication Date
NO20083369L true NO20083369L (no) 2008-10-24

Family

ID=38226290

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083369A NO20083369L (no) 2006-01-27 2008-08-01 Anvendelse av substituert 2-imidazol av imidazolinderivater

Country Status (15)

Country Link
US (1) US7875645B2 (no)
EP (1) EP1981497A2 (no)
JP (1) JP2009524617A (no)
KR (1) KR20080080410A (no)
CN (1) CN101374516A (no)
AR (1) AR059183A1 (no)
AU (1) AU2007209381A1 (no)
BR (1) BRPI0707315A2 (no)
CA (1) CA2637312A1 (no)
IL (1) IL192884A0 (no)
NO (1) NO20083369L (no)
RU (1) RU2008130455A (no)
TW (1) TW200738233A (no)
WO (1) WO2007085557A2 (no)
ZA (1) ZA200806456B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592362B2 (en) * 2006-01-19 2009-09-22 Pfizer Limited Substituted imidazoles
CA2675221C (en) 2007-02-02 2016-02-23 F. Hoffmann-La Roche Ag Novel 2-aminooxazolines as taar1 ligands
US8242153B2 (en) * 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
PT2424843E (pt) * 2009-04-30 2014-06-02 Novartis Ag Derivados de imidazol e seu uso como moduladores de quinases dependentes de ciclina
UY32858A (es) 2009-08-31 2011-03-31 Abbott Healthcare Products Bv Derivados de (tio)morfolina como moduladores de sip
US8354441B2 (en) * 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
TW201643169A (zh) 2010-07-09 2016-12-16 艾伯維股份有限公司 作為s1p調節劑的螺-哌啶衍生物
CN103224468A (zh) * 2013-05-10 2013-07-31 范强 四氢唑林的合成方法
ES2909709T3 (es) 2016-05-12 2022-05-10 Heptares Therapeutics Ltd Inhibidores del receptor 2 activado por proteasa
EP3463359A4 (en) * 2016-06-02 2020-08-26 Purdue Pharma LP SPURENAMINE-ASSOCIATED RECEPTOR-1 AGONISTS AND PARTIAL AGONISTS FOR PAIN MANAGEMENT
JP7413346B2 (ja) 2019-03-06 2024-01-15 第一三共株式会社 ピロロピラゾール誘導体
CN110041261B (zh) * 2019-05-24 2022-06-24 广东先强药业有限公司 一种盐酸萘甲唑啉的制备方法
EP3989935A4 (en) * 2019-07-30 2023-07-26 Cellix Bio Private Limited COMPOSITION AND METHODS FOR THE TREATMENT OF ANAL AND RECTAL DISORDERS
TW202132311A (zh) 2019-10-31 2021-09-01 美商Ｅ 斯蓋普生物股份有限公司 S1p受體調節劑之固體形式
CN110922361B (zh) * 2019-11-21 2021-01-08 武汉大安制药有限公司 一种依托咪酯氧化杂质及其制备方法
KR20230058066A (ko) * 2020-08-27 2023-05-02 큐라센 테라퓨틱스, 인코포레이티드 α1A-아드레날린성 수용체 작용제 및 사용 방법
CN113754524B (zh) * 2021-09-26 2023-08-22 济源市恒顺新材料有限公司 一种间氟苯甲醛生产制造方法
WO2023183394A1 (en) * 2022-03-24 2023-09-28 Curasen Therapeutics, Inc. Alpha 1a-adrenergic receptor agonists and methods of use
CN115784996A (zh) * 2023-02-13 2023-03-14 南京海鲸药业股份有限公司 一种盐酸羟甲唑啉的合成方法及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6551E (fr) 1905-07-27 1906-12-17 Carlo Chiesa Séchoir à tambour rotatif, démontable et transportable, et fonctionnant à ciel ouvert, pour cocons, céréales, etc.
US2161938A (en) * 1934-07-31 1939-06-13 Soc Of Chemical Ind Imidazolines
US2457047A (en) * 1946-02-13 1948-12-21 Monsanto Chemicals 2-(2'-thenyl)-4, 5-dihydroimidazoles and process for making the same
US2778836A (en) * 1954-04-02 1957-01-22 Union Chimique Belge Sa Substituted 2-methyl-delta2 imidazolines
US2744909A (en) * 1955-06-27 1956-05-08 Bristol Lab Inc 2-(ortho-phenylbenzyl) imidazoline and acid addition salts
US2744910A (en) * 1955-06-27 1956-05-08 Bristol Lab Inc 2-(ortho-benzylbenzyl)-imidazoline and acid addition salts
US2919274A (en) * 1957-09-17 1959-12-29 Sahyun Melville Amidines
DE1121054B (de) * 1960-11-23 1962-01-04 Merck Ag E Verfahren zur Herstellung eines neuen Imidazolinderivates und dessen Saeureadditionssalzen
ES323985A1 (es) * 1966-02-26 1966-12-16 Blade Pique Juan Procedimiento para la obtenciën de derivados del imidazol
DE1617618B2 (de) * 1966-06-18 1976-05-20 Merck Patent Gmbh, 6100 Darmstadt Schleimhautabschwellende mittel zur lokalen applikation
US3377247A (en) * 1967-04-28 1968-04-09 Dow Chemical Co Antidepressant method
US3586695A (en) * 1968-01-26 1971-06-22 Dow Chemical Co Substituted imidazolinyl indoles
US3660423A (en) * 1970-02-13 1972-05-02 Dow Chemical Co 2-(substituted benzyl)methyl-2-imidazolines
GB1333471A (en) * 1971-01-27 1973-10-10 Labaz Imidazoline derivatives and process for preparing the same
GB1538097A (en) * 1976-01-26 1979-01-10 Lafon Labor Substituted phenyl-amidines
US4540705A (en) * 1983-03-14 1985-09-10 Sterling Drug Inc. Antidepressant imidazolines and related compounds
US4665095A (en) * 1985-12-11 1987-05-12 Abbott Laboratories Use of 2-[(3,5-dihalo-4-aminobenzyl)]imidazolines to stimulate alpha-1 adrenergic receptors and to treat nasal congestion
CS261294B1 (cs) * 1987-07-17 1989-01-12 Miroslav Protiva 2-(2-(Fenylthio)benzyl)-2-imidazolin a jeho oxalát
US5969137A (en) * 1996-09-19 1999-10-19 Virginia Commonwealth University Benzylamidine derivatives with serotonin receptor binding activity
CA2232467A1 (en) * 1997-03-20 1998-09-20 Richard A. Glennon Imidazoles with serotonin receptor binding activity
DK0924209T3 (da) * 1997-12-19 2003-08-25 Lilly Co Eli Hypoglykæmiske imidazolinforbindelser
ES2150378B1 (es) * 1998-08-07 2001-07-01 Esteve Labor Dr Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p.
CA2246027A1 (en) * 1998-08-27 2000-02-27 Virginia Commonwealth University Benzylamidine derivatives with serotonin receptor binding activity
US6455734B1 (en) 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
AR024077A1 (es) * 1999-05-25 2002-09-04 Smithkline Beecham Corp Compuestos antibacterianos
JP2001302643A (ja) * 2000-04-21 2001-10-31 Suntory Ltd 環状アミジン化合物
EP1319070A2 (en) * 2000-09-12 2003-06-18 Oregon Health & Science University Mammalian receptor genes and uses
AU2007209382A1 (en) 2006-01-27 2007-08-02 F. Hoffmann-La Roche Ag Use of 2-imidazoles for the treatment of CNS disorders
DE602007004949D1 (de) 2006-01-27 2010-04-08 Hoffmann La Roche Verwendung von 4-imidazol-derivaten für zns-erkrankungen

Also Published As

Publication number Publication date
TW200738233A (en) 2007-10-16
RU2008130455A (ru) 2010-03-10
WO2007085557A3 (en) 2007-09-20
CN101374516A (zh) 2009-02-25
ZA200806456B (en) 2009-11-25
BRPI0707315A2 (pt) 2011-05-03
CA2637312A1 (en) 2007-08-02
EP1981497A2 (en) 2008-10-22
AU2007209381A1 (en) 2007-08-02
KR20080080410A (ko) 2008-09-03
US20070197621A1 (en) 2007-08-23
JP2009524617A (ja) 2009-07-02
WO2007085557A2 (en) 2007-08-02
US7875645B2 (en) 2011-01-25
IL192884A0 (en) 2009-08-03
AR059183A1 (es) 2008-03-12

Similar Documents

Publication Publication Date Title
NO20083369L (no) Anvendelse av substituert 2-imidazol av imidazolinderivater
UA98951C2 (ru) 2-аминооксазолины и лекарственное средство, которое их содержит
NO20083356L (no) Anvendelse av 4-imidazolderivater for CNS sykdommer
NZ602754A (en) Substituted 1,3-benzothiazepines useful in treating metabolic disorders
BR112013024312A2 (pt) derivados de amina heterocíclica
MX2009003801A (es) Aminometil-4-imidazoles.
AR063326A1 (es) Aminometil-2-imidazoles, medicamentos que los contienen, metodo de preparacion, y usos para el tratamiento de trastornos asociados al sistema nervioso central
JP2002523491A5 (no)
NO20075623L (no) Benzodioksan- og benzodioksolanderivater og deres anvendelse
BR112013030698A2 (pt) derivados de benzamida substituídas
BR112012027640A2 (pt) composto, composição farmacêutica uso de um composto, e, métodos de preparar uma composição farmacêutica, de inibir a função da 11beta-hidroxiesteroide desidrogenase do tipo 1 e de tratamento ou prevenção de um distúrbio
AU2014368476B2 (en) Oxindole derivatives, preparation thereof and therapeutic use in the treatment of AMPK-related diseases
HRP20120227T1 (hr) 3-(1,3-benzodioksol-5-il)-6-(4-ciklopropilpiperazin-1-il)piridazin, njegove soli i solvati te njegova uporaba kao antagonista histaminskog h3 receptora
ECSP11010782A (es) Derivados de 4,5-dihidro-oxazol-2-ilo
BR112014015832A2 (pt) derivados heterocíclicos como receptores associados com aminas vistigiais (taars)
JP2008523075A5 (no)
TW200817383A (en) Novel chromene and thiochromene carboxamide derivatives, methods for preparing same and therapeutic applications of same
Lu et al. Scaffold hopping approach to a new series of smoothened antagonists
MX2010009643A (es) Derivados de 2-aminoquinolina como antagonistas del receptor 5-hidroxitriptamina (5a).
MX2010005225A (es) Derivados de fenilpirazol.
NO20073248L (no) Derivater av isotiazol-3(2H)-on 1,1-dioksider som lever X reseptor modulatorer
TW531538B (en) Oxazolidinones
PE20090115A1 (es) Derivados de indol-2-il-piperazin-1-il-metanona
CL2008003053A1 (es) Compuestos derivados de (4-(piperazin-1-il)fenil)-amida del acido isoxazol-4-carboxilico; composicion farmaceutica, util para tratar tejido nervioso, depresion, ansiedad, adiccion a drogas, falla cardiaca, desordenes del sueno, obesidad, desordenes metabolicos, entre otras, a travez de la modulacion del receptor npy y2.
NO20054381L (no) 1,3-substituerte sykloalkylderivater med sure, som oftest heterosykliske grupper, deres fremstilling og deres anvendelse som legemiddel

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application